Fig. 5

MAP17 expression predicts sensitivity to bortezomib in lung adenocarcinoma. a Bortezomib sensitivity in low-, medium- and high-MAP17-expressing lung adenocarcinoma cell lines. b Sensitivity of low- and high-MAP17-expressing adenocarcinoma cell lines to bortezomib and to another proteasome inhibitor, MG132, obtained from the GDSC database. c Bortezomib sensitivity in the Calu-3 lung adenocarcinoma cell line after MAP17silencing and in the H1975 lung adenocarcinoma cell line after MAP17 overexpression. d Assessment of MAP17 mRNA expression in adenocarcinoma PDX models. e Tumour growth assessment (left) and survival analysis (right) in three bortezomib-treated adenocarcinoma PDXs with differential MAP17 expression. f Western blot showing activation of oncogenic signalling- and autophagy-related pathways in bortezomib-treated and control adenocarcinoma PDX models